TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02098629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Infusion
Description: Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
Study: NCT00335816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study: NCT01945632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional gracey curettes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertically oscillating ultrasonic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: piezoelectric ultrasonic scraper
Study: NCT02636127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: one blood sample will be done for dosage and role of Fractalkine in the serum.~- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release.

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: one blood sample will be done for dosage and role of Fractalkine in the serum.~- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release.
Study: NCT01188733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting octreotide 10mg
Description: Comparison of different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting Octreotide 30mg
Description: Comparison of drug doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Comparison of drug doses
Study: NCT01104662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study: NCT00335816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT04026828

Intervention type: GENETIC
Intervention: Periodontitis Group
Description: Periodontitis group consists of both chronic and aggressive periodontitis patients

Intervention type: GENETIC
Intervention: Periodontitis Group
Description: Periodontitis group consists of both chronic and aggressive periodontitis patients
Study: NCT00335816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01104662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study: NCT00335816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01104662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study: NCT03457116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: 20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
Study: NCT00335816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT03457116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Ibuprofen 400mg for post-operative pain
Study: NCT01104662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semi-Synthetic Penicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semi-Synthetic Penicillin
Study: NCT00335816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT01104662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semi-Synthetic Penicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semi-Synthetic Penicillin
Study: NCT02779816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen device
Description: Adaptive pen device
Study: NCT02472392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit anti-thymocyte globulin
Description: Active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit anti-thymocyte globulin
Description: Active treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: comparitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: comparitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: comparitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: comparitor
Study: NCT01997554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: An extra blood sample of 10 ml is collected
Study: NCT03125928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Monoclonal antibody
Study: NCT01997554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: An extra blood sample of 10 ml is collected

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: An extra blood sample of 10 ml is collected
Study: NCT06542965

Intervention type: OTHER
Intervention: Non-Interventional Research
Description: Non-Interventional Research

Intervention type: OTHER
Intervention: Non-Interventional Research
Description: Non-Interventional Research
Study: NCT03887689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified prolonged exposure
Description: Participants will receive three sessions of modified prolonged exposure therapy.
Study: NCT04459195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Minute Static Stretching
Description: Stretching applications will be applied to the first group for 2 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Minute Static Stretching
Description: Stretching applications will be applied to the first group for 5 minutes. Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 30 seconds of rest and and the individuals will be asked to participate in the exercise actively.
Study: NCT03533946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until Prostate Specific Antigen (PSA) progression or intolerable toxicities.
Study: NCT04095299

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 50.4 Gy to the tumor and elective volume
Description: Standard radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume
Description: Experimental radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine 825 mg/m2 twice daily on weekdays
Description: Standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 825 mg/m2 twice daily on weekdays
Description: Standard chemotherapy
Study: NCT00198497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Description: Hyaluronidase 55 IU in saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Description: Hyaluronidase 75 IU in saline solution
Study: NCT00589095

Intervention type: OTHER
Intervention: dynamic contrast enhanced magnetic resonance imaging
Description: dynamic contrast enhanced MRI using contrast agent gadodiamide
Study: NCT00794079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: 4 grams per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: 4 grams per day for 8 weeks
Study: NCT03125928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Monoclonal antibody
Study: NCT02293772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxic ambulatory
Description: 21 days confinement in normobaric hypoxic (FiO2 = 14%) environment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Bedrest
Description: 21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxic Bedrest
Description: 21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
Study: NCT04182815

Intervention type: DEVICE
Intervention: Robotic assisted bronchoscopy
Description: Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
Study: NCT00482820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention-bias training
Description: one group recive an attention training away from threat. The second group, the controll group, recive a placebo training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: attention-bias training
Description: one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
Study: NCT01618084

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tritanium acetabular component
Description: Total hip arthroplasty using a tritanium uncemented acetabular component

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tritanium acetabular component
Description: Total hip arthroplasty using a tritanium uncemented acetabular component
Study: NCT03490214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive transcutaneous imaging of subcellular muscle components

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography
Description: Non-invasive transcutaneous imaging of subcellular muscle components
Study: NCT03040284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echodia® hand-held equipment (ELIOS)
Study: NCT03340584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Nine Castle Net Format Taping
Description: The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.

Intervention type: OTHER
Group type: OTHER
Intervention: traditional rehabilitation
Description: traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
Study: NCT01199926

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 4000 IU of vitamin D per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000 IU of vitamin D per day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
Study: NCT01041014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional medical interpreter
Description: All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
Study: NCT00717821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-epoetin Beta
Description: Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Beta
Description: Participants who are receiving SC or IV epoetin beta will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Participants who are receiving SC or IV darbepoetin alfa will continue to receive the treatment at the same dose, same administration intervals, and the same route of administration. When necessary, dose adjustments will be performed according to SmPC. Total duration of treatment will be up to 48 weeks.
Study: NCT02986282

Intervention type: DEVICE
Group type: OTHER
Intervention: ABI measurement using both doppler and oscillometric method
Study: NCT03453879

Intervention type: OTHER
Intervention: no intervention
Description: No intervention - only observation of teams delivering acute obstetric care
Study: NCT01214369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of Supplementary Injection
Description: Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of Supplementary Injection
Description: Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
Study: NCT04464044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verofilcon A toric contact lenses
Description: Daily disposable toric soft contact lenses
Study: NCT04223050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Administering oxygen to achieve the desired peripheral oxygen saturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Administering oxygen to achieve the desired peripheral oxygen saturation
Study: NCT05059756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS
Description: PTNS and PFR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham PTNS
Description: Sham PTNS and PFR
Study: NCT04689477

Intervention type: DEVICE
Intervention: Vascular occlusion test
Description: The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.

Intervention type: DEVICE
Intervention: Vascular occlusion test
Description: The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
Study: NCT04307459

Intervention type: OTHER
Intervention: standard operating procedures
Description: standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.
Study: NCT04689477

Intervention type: DEVICE
Intervention: Vascular occlusion test
Description: The ischemic challenge will consist in a standardized Vascular Occlusion Test (VOT), as previously described in the literature. Briefly, a blood pressure cuff will be placed proximal to the forearm, and rapidly inflated at 40 mmHg above systolic pressure, and kept inflated during three minutes. Then the cuff will be rapidly deflated. The resulting deoxygenation (DeO2) and reoxygenation (ReO2) slopes will be reported as change in O2 saturation over time.
Study: NCT04436692

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nudging
Description: Use nudging approach by using smaller plates and glasses and increasing the availability of fruits and vegetables
Study: NCT04576546

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: Supplementation of D-chiro-inositol (1000 mg/die), starting at least 4 weeks before rFSH administration

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol
Description: Supplementation of myo-inositol (4 g/die), starting at least 4 weeks before rFSH administration
Study: NCT02848599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Study: NCT03724877

Intervention type: DRUG
Intervention: Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)
Description: (LABA-LAMA-ICS)

Intervention type: DRUG
Intervention: Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)
Description: (LABA-LAMA)
Study: NCT00968981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Daily oral repeating dose